Short-course Hypofractionated Radiotherapy in Combination With Raltitrexed and Tislelizumab

NCT06408584 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 25

Last updated 2024-05-21

No results posted yet for this study

Summary

The goal of this observational study was to explore the safety and efficacy of short course hypofractionated radiotherapy combined with Raltitrexed and Tislelizumab in the treatment of patients with relapsed or advanced esophageal squamous cell carcinoma.

Conditions

Sponsors & Collaborators

  • Anhui Provincial Hospital

    lead OTHER_GOV

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-01
Primary Completion
2027-03-01
Completion
2027-03-01

Countries

  • China

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06408584 on ClinicalTrials.gov